Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PCOL 310 > PCOL 310 > Flashcards

PCOL 310 Flashcards

1
Q

Federal Food, Drug, and Cosmetic Act of 1938

A

-Required manufacturers demonstrate safety of new drugs prior to marketing
-Allowed FDA to inspect manufacturing facilities
-Defined the following key terms: drug, device, cosmetics and labeling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Durham-Humphrey Amendment of 1951

A

distinguishes prescription from non-prescription

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Kefauver-Harris Amendment of 1962

A

-required that manufacturers prove the effectiveness of drug products before they go on the market, and report any serious side effects
-required that evidence of effectiveness be based on adequate and well-controlled clinical studies conducted by qualified experts
-gave FDA 180 days to approve a new drug application

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Orphan Drug Act of 1983

A

-drugs intended to treat rare diseases and conditions
-provides pharmaceutical manufacturers tax and licensing incentives to develop them

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

food

A
  • articles used for food or drink for man or other animals
  • chewing gum
  • articles used for components of any such article.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

drug

A
  • Articles recognized in the official USP/NF or Homeopathic Pharmacopoeia, or any supplement to any of them
  • Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals
  • Articles other than food intended to affect the structure or function of the body of man or other animals

(no destinction b/w prescription vs. non-prescription & human vs. animal)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Waxman Hatch Amendment of 1984-

A

Drug price Competition and patent term restoration act
-Streamlined generic drug approval process to make them more readily available
-created certain market and patent exclusivity periods for both branded and generic drug companies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Labeling

A

All labels and other written, printed, or graphic matter on any container or wrapper or material accompanying the product
-Package insert
-drug advertisement
-information in publications ( PDR)
-Promotional materials such as newsletter and literature

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

GMP

A

Good manufacturing practice
-Applies to manufacturers, not pharmacies
-Drugs subject to GMP are selected based on medical importance,market share, number of similar products in the marketplace, and previous compliance record of the manufacturer.
- Every two years manufacturers must register with the FDA to be inspected.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Non prescription drug labeling

A

-Display panel
-Must have detailed usage and warning info so consumers can properly choose and use the products

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Principal Display Panel

A

-Panel of the label that is most likely to be displayed, presented, shown or examined by the end user

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Commercial Container Label

A

for the health care professional and not the consumer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Drug listing act of 1972

A

Required manufacturers to provide the FDA with a current list of all drugs manufactured, prepared, propagated,compounded, or processed by it for commercial distribution

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

NDC code

A

1234-5678-90
1234= manufacturer
5678=drug
90=package

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Seizure

A

The physical isolation of a drug while FDA or state agency files civil lawsuit
-What drugs can the FDA seize?
-Mis branded or adulterated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Recall

A
  • The correction or removal, and notification to the company, of a product that is in violation of the law.
    -3 levels of recall
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

cosmetic

A

Articles intended to be rubbed, poured, sprinkled or sprayed on, introduced into , or otherwise applied on the human body, or any part thereof for cleansing, or altering the appearance.
-Articles intended for use as a component in any such articles, not including soap

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Dietary Supplement

A

A product taken by mouth that is intended to supplement the diet and contains one or more dietary ingredients, Including
-Vitamins
-Minerals
-Herbs or other botanicals
-amino acids
-other substances found in the human diet such as enzymes
-Must be labeled as such and must not be represented as conventional food or as the sole item of a meal of the diet
-Conventional foods are foods that are not dietary supplements (Nutrition facts vs supplement facts panel)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Device

A

An instrument, apparatus, machine, contrivance, implant, in vitro Reagent, or other similar or related article, including any part component or accessory intended to diagnose or treat a disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

label

A

display of written material on the products container or on the outside container or wrapper

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

class 1

A

reasonable probability that the use of, or exposure too a violative product will cause serious adverse health consequences or death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

class 2

A

Use of or exposure too may cause a temporary or medically reviserable adverse health consequence,or where the probability of serious health consequences is remote.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

class 3

A

Use or exposure to the product is not likely to cause serious adverse health consequences

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

IND

A

Investigational New drug application
-Evaluated by: Office of new drugs (OND) & Center for Drug Evaluation and Research (CDER)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Institutional Review Board (IRB)
-"Pay to Play" -Support timely review -Options for waivers/reduction/refunds -Applicable for small businesses, first time applicants
26
Risk Evaluation and Mitigation Strategies (REMS)
-FDA can require REMS for certain medications with serious safety concerns to ensure benefits outweigh the risks
27
Standard FDA review path
12 months
28
Priority FDA review path
8 months -Demonstrate that the drug or biologic has potential to significantly improve safety of effectiveness of treatment, diagnosis, prevention of serious/life threatening conditions -FDA has 60 days to review an NDA
29
Abbreviated New Drug Application
-Process where generic products are approved after expiration of patent held by innovator company -Requires proof that generic's pharmacokinetics, bioavailability and clinical activity are similar to the innovator product
30
Supplemental new drug application SNDA
-Submitted after the NDA approval - Covers change in synthesis, production procedures, manufacturing locations, indications
31
Agencies responsible for drug advertising
-FDA regulates prescription drug advertising -Federal Trade Commission: regulates non prescription drugs under the federal trade commission act
32
Non clinical testing objectives
Does compound or molecule work How can we deliver it to the right cell/tissues/ organs Is it safe Can we manufacture it ensuring safety, practicality, stability
33
Types of Non clinical trial studies
In Vitro- Controlled enviornment outside living organism In Vivo- Using a whole, live living organism In Silicio- on a computer
34
Pharmacodynamics studies
method of action vs mode of action
35
Mechanism
Biochemical interaction through which a drug substance produces a pharmacological effect
36
Mode
describes functional or anatomical changes at the cellular level resulting from the exposure of a living organism to a substance- action on specific receptors or enzymes
37
Pharmacokinetic studies
Determine the highest and lowest concentration in the body after med administration, movement of drugs within the body
38
ADME
absorption, distribution, metabolism, excretion
39
Good Laboratory Practice
The batches of the active ingredient must be qualified and produced according to the GMP guidelines
40
CMC
Chemistry, manufacturing and control. Term used in the context of production and quality control of drugs or drug candidates.
41
Non-clinical outcomes that can STOP development
-Discovery of organ toxicity -Identification of poor pharmacokinetic properties
42
IACUC
Institutional Animal Care and Use committee. -must review all animal experiment protocols
43
AAALAC
Association for assessment and accreditation of laboratory animal care -Non-profit organization that accredits research facilities for compliance with the guide
44
Types of Toxicity studies
-Local tolerance studies -genotoxicity studies -carcinogenicity studies -reproduction toxicity
45
No Observed Adverse Effect Level (NOAEL)
The highest dose, among doses tested in a study, that demonstrates no significant difference from effects measured in control animals.
46
Minimal Anticipated Biological Effect Level (MABEL)
Used in establishing first human dose
47
IND purpose
-Notifies regulators of intent to begin clinical studies in US -Provides preclinical data indication that the drug is reasonably safe to administer to humans -provides information about manufacturing process and chemistry background -Describes the initial clinical study being proposed -Provides insurance that an Institutional review board will approve the study before it begins
48
Commercial IND
-Pharmaceutical companies whose ultimate goal is to obtain marketing approval for new products
49
Research IND
-(Non commercial) submitted by physicians who initiate and conduct an investigation
50
Product development (Clinical Investigation) IND
submitted by corporate entity or physician who both initiates and conducts the investigatio
51
Clinical treatment (Expanded Access INDS)
Use of an IND outside of a clinical trial by patients, with serious or life treating conditions and no comparable or satisfactory alternative therapy exists, who do not meet enrollment criteria for the clinical trial process
52
Criteria for expanded access programs
1) Presence of life threatening condition with no comparable alternative treatment 2) Potential benefit to patient justifies the risk 3)Use of the IND will not interfere with it clinical investigative process or compromise its development
53
Right to Try act
Permits/allows eligible patients to have access to eligible investigational drugs
54
IND module contents
Module 1: Administrative info Module 2: Summaries Module 3: Quality Module 4: Non clincal studies reports Module 5: Clinical study reports
55
Clinical Hold
an order issued by the FDA to the sponsor of an IND to delay a proposed clinical investigation or suspend an ongoing clinical investigation
56
-vastatin
Cholesterol lowering
57
-oxetine
anti depressant
58
-sartan
Lowers BP
59
-afil
erectile dysfunction
60
-lukast
asthma
61
-azepam
anti anxiety
62
-coxib
anti-inflammatory
63
-formin/glitazone
Diabetes
64
-prazole
acid reducer
65
-vir
anti virals
66
When is IND not required?
- Certain research involving marketed drug products - bio availability or bio equivalence drugs ( using unapproved versions or approved drugs)
67
What can be patented?
-chemical substance, pharmaceuticals -processes, methods, uses - products, devices, systems
68
Five year exclusivity period
FDA gives exclusivity period for new chemical entity (NCE), during which no other company can submit a ANDA
69
FDA vs Patent Protection
FDA=5 years Patent Protection= 20 years
70
FDA orange book
where manufacturers list their patents
71
Patent and Utility Models
New inventions
72
Copy Right
Original creative or artistic forms -automatically exists
73
Trademarks
Distinctive ID of products or services
74
Registered design
external appearance
75
Trade secrets
Valuable information not known to the public
76
NDA: A request to market the drug
-clinical safety and efficacy data -clinical pharmacokinetic data -non clinical pharmacology/toxicology data -chemistry data -Package labeling -administrative information (ie patent information, debarment certification)
77
Types of NDA
-New Molecular entity (NME ) -New active ingredient -New dosage form -New combination -New formulation or new manufacturer - New indication, same manufacturer( No longer used) -Drug already marketed, but without approved NDA -Rx to OTC
78
Efficacy Supplement
defined based on the type of change that is being made, not the type of data the supplement contains -sponsor should submit a redline version of the proposed labeling so the FDA can see the proposed changes
79
Priority Review
Drug product has the potential to provide - S and E therapy where there is no satisfactory alternative -A significant improvement compared to marketed products
80
Accelerated Approval
allows approval based on a surrogate endpoint
81
Fast- Track Designation
for new drugs intended to treat serious or life threatening conditions, demonstrate the potential to address unmet medical needs
82
Rolling Submission
A drug company can submit completed sections of the NDA review by FDA, instead of waiting until the entire application is done
83
Breakthrough Designation
FDASIA's designation for drugs that may treat a serious or life threatening condition
84
PDUFA vs the program
applies to all NME's, NDA's and original BLA's (fiscal years 2013-2017) Modifications- -additional 2 months added to the review period - Priority 6 months= 8 months standard 10 months = 12 months - More frequent communication with the applicant
85
Drug approval process 1-5
1) pre non clinical animal studies 2) IND application 3) Phase 1 20-80 applicants testing for safety 4) Phase 2 100's of volunteers testing for efficacy 5) Phase 3 100 to 1000 volunteers, gather biological info, uses drug in combination of other drugs
86
Drug approval process 6-12
6) Review meeting 7) NDA application 8-9) Application reviewed 10)Drug labeling 11) facility inspection 12) Drug approval or denial
87
Clinical Investigation
any experiment in which a drug is administered or dispensed to, or used involving, one or more human subjects.
88
sponsor
person who takes responsibility for and initiates clinical investigation
89
Sponsor- investigator
The person who both initiates and conducts a clinical investigation the drug is administer/dispensed under their direction
90
IND process
Day 0-7 : receipt and assignment of reviewers Day 8-27: review and safety meetings Day 25-30: saftey decision and notification
91
How do drugs get their names?
Chemical name: Describes atomic or molecular structure generics- assigned by U.S adopted names brand- developed by the company requesting approval of that drug
92
An expanded access use IND would be most likely to be granted where:a) An approved drug has demonstrated safety and the patient is in imminent life threatening stages of an illness.b) An unapproved drug has demonstrated efficacy and there are some drugs available to treat the patient's condition c) An unapproved drug has some demonstrated safety and efficacy and the patient is in life threatening stages of an illness d) An unapproved drug has some demonstrated safety and efficacy and the patient is already enrolled in the clinical studies for the drug.
C
93
During phase 1 of a clinical trial for a drug under a Investigational New Drug Application a) The drug is tested on a large number of animals to determine efficacy b) The drug is tested on a large number of animals to determine safety c) The drug is tested on a limited number of healthy patients to determine efficacy d) The drug is tested on a limited number of healthy patients to determine safety
D
94
Under the federal FDCA, a drug a) "Caution: Federal law prohibits dispensing without prescription" or "Rx Only."b) Is a product intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals.c) Is a product intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human bodyd) Is a product where the container or labeling of which bears the trademark, trade name of a drug manufacturer
B
95
Is caffeine classified as a:a) Drug b) Supplement c) Food
a) drug
96
IS infant formula classified as a) Drug b) dietary supplement c) food
b) dietary supplement
97
GxP purpose
Good (Anything) practice -guidelines are there to ensure a product is safe and meets its intended use, guides quality manufacture in regulated industries Central aspects: Traceability, accountability
98
Traceability
the ability to reconstruct the development history of a drug or medical device
99
accountability
the ability to resolve who has contributed what to the development and when
100
True or False: The primary objective of GLP's are to ensure scientific validity and good science in the non-clinical testing of compounds
FALSE does not ensure good science... it does ensure the uniformity, consistency, reliability, reproducibility, quality and integrity of chemical non-clinical safety tests
101
true or false: GMP guidelines provide prescriptive instructions on how to manufacture products
FALSE they are a series of general principles and minimum requirements that must be observed during manufacturing
102
GCP enforces which of the following aspects of clinical trials?-ethical aspects of a clinical study-standards on how clinical trials should be conducted-the roles and responsibilities of clinical trial sponsors and clinical research investigators-all of the above
all of the above
103
detailing
face to face promotional activities, representatives typically visit prescribers to pitch their drug (ex: meals, gifts )
104
samples
providing free medications samples to prescribers
105
educational and promotional meetings
leaders discuss the use of drugs
106
indirect marketing
sponsorships and grants
107
Who regulates advertisement to consumers?
-FTC regulates ads or OTC drugs -FDA regulates ads for prescription drugs, medical devices, lasers and contact lenses
108
Direct to consumer (DTC) advertising
any promotional effort by pharmaceutical company to present prescription drug info to the general public through the law media.

PCOL 310 (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions